SRC-Search ads

Why keep gambling on generalist recruiters when you can cut straight to measurable results? SRC-Search uses clear criteria—track records, market fit, and revenue impact—to connect you with commercial -omics professionals who have already delivered. You spend less time screening and more time growing the part of your business that matters most.

𝗘𝗽𝗶𝘀𝗼𝗱𝗲 𝟭 𝗶𝘀 𝗻𝗼𝘄 𝗹𝗶𝘃𝗲..! And I will be honest, this is a special moment. Months of hard work, and it is finally out in the world 😱. A big warm thank you to my first guest, Luciano Martelotto. What a wonderful person to kick off the series with. I am nervous and excited, but definitely more nervous. Luckily recruiters talk more than they listen, and we usually hand the platform to our candidates, so no change there. Still, listening back to my own voice has been a special kind of torture. I do not know how all of you have put up with me for the past 15 years. A quick recap of why we are doing this. The idea is to give some of the best people in across the -𝗼𝗺𝗶𝗰𝘀 𝘄𝗼𝗿𝗹𝗱 the space to share their story, their hopes and dreams, their failures, their advice and their predictions. It has given me a real look into their world, and I am proud to share it with you. Luciano, a special thank you to you. You are awesome. Keep being you! Your love and passion for science run through everything you say, read, create and do. We are lucky to have you. A shout out too to Julia G., who worked through hours of raw video to make this come together, and to the whole SRC-Search 𝘁𝗲𝗮𝗺, who kept recruitment moving like no one else whilst I "discovered podcasting". I can only imagine their group chat. 𝗦𝗼𝗺𝗲 𝗼𝗳 𝘁𝗵𝗲 𝘁𝗼𝗽𝗶𝗰𝘀 𝗶𝗻 𝘁𝗵𝗶𝘀 𝗲𝗽𝗶𝘀𝗼𝗱𝗲: • Benchmarking, and the better question nobody is asking • Why Luciano loves the tools he argues hardest with • The one thing he would take back • His advice for the next generation, in roughly four words Have a listen, and let me know what you think. Subscribe so you do not miss the next one, share it with someone who would enjoy it, and tell me in the comments: who would you love to hear on the show? Links to your favourite podcast app in the comments.

𝗧𝗵𝗲 𝗯𝗲𝘀𝘁 𝗽𝗲𝗼𝗽𝗹𝗲 𝗶𝗻 𝗼𝘂𝗿 𝗳𝗶𝗲𝗹𝗱 𝗿𝗮𝗿𝗲𝗹𝘆 𝗴𝗲𝘁 𝘁𝗼 𝘁𝗲𝗹𝗹 𝘁𝗵𝗲𝗶𝗿 𝘄𝗵𝗼𝗹𝗲 𝘀𝘁𝗼𝗿𝘆. 𝗡𝗼𝘄 𝘁𝗵𝗲𝘆 𝗱𝗼! Some exciting news to share at SRC-Search: 𝗧𝗵𝗲 𝗟𝗶𝗳𝗲 & 𝗦𝗰𝗶𝗲𝗻𝗰𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁 Starting a podcast in 2026 is hardly original, granted, but this one is all about the guests, not the format. We wanted to give some of the most interesting people in life science the time to really share their story. These are inspirational figures, and what we were after were real conversations, not soundbites, so yes, the episodes run a little longer. Sorry not sorry. We celebrate their careers and talk through the challenges in the market, then look ahead to where all of this is going. They share their words of wisdom, with advice for those coming up. Because it should be fun too, we play a few games along the way. Every guest has been a pleasure and an honour to talk with, and I hope these conversations become the kind of thing you listen to whenever suits you, whether that is your lunch break, a Sunday afternoon stroll, a workout, or a long drive to a customer far away. With eight episodes to come, I am very excited as well as a little nervous for the months ahead. My warmest thanks go to every guest for their time and their honesty, and to Julia G., who worked through hours and hours of raw video (argh my voice 😅) to make all of this come together. Leaving you with a clue for E01: the man from down under, the closest thing single cell and spatial has to a GOAT, the man who appears to need no sleep and who continues to do an amazing job of highlighting great science and bringing this whole community together. More soon.

Get the latest jobs and industry news

𝗔𝗔𝗖𝗥 𝟮𝟬𝟮𝟲: 𝘄𝗵𝗼 𝗜 𝗮𝗺 𝘄𝗮𝘁𝗰𝗵𝗶𝗻𝗴 (𝗽𝗮𝗿𝘁 𝟮): Countdown clock to the exhibition hall opening. T-minus 2 hours! Weather looks a bit meh today. Perfect timing to remain indoors and talk multi-omics 🤝. Part 2 of my American Association for Cancer Research watchlist. If you missed part 1, it's here: [https://lnkd.in/eVKJbrmJ]. 10 more: Each doing something genuinely different. Some of these you have definitely heard of. Some you will soon. AEGEA Biotechnologies: Switch-Blocker nucleic acid chemistry detects variants below 0.01% for EGFR, KRAS, ESR1 and friends. Validated across 30,000+ patient samples. A quietly formidable player in rare mutation detection. Deepcell: Most interesting morphology platforms. REM-I platform, Human Foundation Model trained on 2+ billion single-cell images. Just launched Deepcell Express: mail in samples, get publication-grade data back. Smart move. DPBIO: Droplet microfluidics done properly. CytoSpark, OMNIdrop, Galaxy, Nebula, ExoStar: the full stack for antibody discovery, single-cell, digital PCR and EV analysis. Enrich Biosystems Inc.: TROVO platform: microfluidics-free rare cell capture and retrieval using dissolvable microwells, 9,128 enrichment ratio published. Everest Biolabs: Extracellular vesicle isolation and characterisation. If EVs become the next liquid biopsy substrate, Everest is positioned for it. FYR Bio: EV-Omics platform built on SPARCs. Just announced an NCI-funded collaboration with NuvOx on glioblastoma liquid biopsy. Intelliseq: iFlow platform for NGS data analysis and clinical interpretation. Just integrated Genomenon's Cancer Knowledgebase for somatic variant calling. Ramona: MCAM multi-camera array microscopy, 24 miniaturised 4K video microscopes in a single instrument. The Vireo system images an entire 96-well plate across five channels in under two minutes. Revolune: Just launched. ZEISS spin-out focused on streamlined multiplex immunofluorescence reagents for spatial biology. Tuesday dinner invite pending 😇. RhoDx, Inc.: liquid biopsy enhancement. PointSuppressor and NexGenAbler suppress wild-type noise and amplify mutant signal, and they plug into any PCR workflow. Twenty companies across two posts. If I missed one you are excited about, put it in the comments, I genuinely want to know. Calendar open to meet: 📅 [https://lnkd.in/ekEzTBwd] See you at the Multi-Omics Mixer: https://lnkd.in/eBZ3mPyx. Check out the latest SRC-Search roles on www.src-search.com. Have a great show everybody 🤞 I love this game!

𝗠𝗮𝗸𝗶𝗻𝗴 𝘁𝗵𝗲 𝗶𝗺𝗽𝗼𝘀𝘀𝗶𝗯𝗹𝗲, 𝗽𝗼𝘀𝘀𝗶𝗯𝗹𝗲. Ever since AGBT, a chocolate wrapper has been living rent-free in my head. My team will tell you this was a targeted attack, as I have a known chocolate problem. We are days out from the big reveal at AACR and going by 10x's own framing, it won't be the obvious next step. It shouldn’t be. I am convinced it is a new platform and my gut says it has to be spatial. But most of what would be new for 10x is already taken by competitors (Bruker/Akoya/Stellaromics): Spatial whole-transcriptome: taken Spatial proteomics: taken Same-cell multiomics: taken 3D spatial: taken Spatial genomics or epigenomics: I wish. Still impossible. Not the launch. So, what is left for 10x Genomics to launch? Let’s start with the easy guess: Chromium. Visium. Xenium. Three platforms, one naming convention. A fourth -ium must be upon us 😆. Now for the harder one. Finding people is what we at SRC-Search do for a living. Finding the right abstracts utilises the same skill. Two abstracts in the AACR supplement are 10x-authored, and read carefully, I think they tell one story. Whole transcriptome at single-cell resolution, with H&E first and spatial second, running on standard Superfrost slides (the pathology consumable every hospital lab already has stacked in a drawer). A new "10x Genomics interactive workspace" where morphology is the primary canvas, not an afterthought. And language that hints at spatial and single-cell collapsing into one assay on one section. That is not a new -omics. That is a new axis. Today, spatial biology lives in core facilities and research labs, with proprietary slides, specialist operators, and research-grade economics that put it out of reach for routine clinical use. After 4/18, if I am reading the abstracts correctly, it moves into pathology labs: slide in, answer out, on the consumables your local hospital already stocks and the workflow your pathologists already know. 𝗧𝗵𝗮𝘁 𝗶𝘀 𝘁𝗵𝗲 "𝗶𝗺𝗽𝗼𝘀𝘀𝗶𝗯𝗹𝗲 𝗺𝗮𝗱𝗲 𝗽𝗼𝘀𝘀𝗶𝗯𝗹𝗲": 𝘁𝗵𝗲 𝗱𝗲𝗽𝗹𝗼𝘆𝗺𝗲𝗻𝘁. The one that turns a research workflow into a clinical one without losing the data quality that made spatial worth doing in the first place. If correct, this would be an amazing leap forward! Making the impossible, possible. I will be at AACR to find out if I am right. 10x Genomics: hope I am not giving it all away. Bribery accepted in dark chocolate. Lindt 78%, by the stack..